NR1H4 and intestinal neoplasm: FXR repressed proliferation of colon cells by inhibiting the MMP7 (matrix metallopeptidase 7), a known intestinal tumor promotor expression; by activating mir-22 repression of CCNA2 (Cyclin A2); and by activating the EGFR/SRC (epidermal growth factor receptor/SRC proto-oncogene) pathway in colon cells (92, 175, 177).